AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) dropped 6.8% during mid-day trading on Friday after Canaccord Genuity Group lowered their price target on the stock from $66.00 to $52.00.

AtriCure (NASDAQ:ATRC – Free Report) had its target price decreased by JPMorgan Chase & Co. from $51.00 to $46.00 in a ...

Karen Prange, a director at $ATRC, sold 6,100 shares of the company on 03-05-2025 for an estimated $232,531. We received data on the trade from a recent SEC filing ...

AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Across the recent three months, 11 analysts have shared their insights on AtriCure ATRC, expressing a variety ... 150 analyst firms and reports on their stock expectations. Analysts typically ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Journey ...

Barclays said in a note Monday that it sees attractive entry points in MedTech stocks, as recent weakness in some sector ...